PRECISION BIOSCIENCES INC — Director's Dealing 2021

Jan 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PRECISION BIOSCIENCES INC (DTIL)
CIK: 0001357874
Period of Report: 2021-01-22

Reporting Person: KANE MATTHEW R. (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-22	Common Stock	M	21514	$0.04	Acquired	1840592	Direct
2021-01-22	Common Stock	S	10218	$13.53	Disposed	1830374	Direct
2021-01-25	Common Stock	M	21514	$0.04	Acquired	1851888	Direct
2021-01-25	Common Stock	S	9695	$13.74	Disposed	1842193	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-22	Employee Stock Option (Right to Buy)	$0.04	M	21514	Disposed	2021-05-17	Common Stock (21514)	Direct
2021-01-25	Employee Stock Option (Right to Buy)	$0.04	M	21514	Disposed	2021-05-17	Common Stock (21514)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	9752	Indirect

Footnotes

F1: Includes 6,651 additional shares acquired under the Company's 2019 Employee Stock Purchase Plan since the reporting person's ownership report filed on September 25, 2019.

F2: The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise for an option grant expiring 05/17/2021, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.60. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.70 to $13.86. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: Includes 1,685 additional shares acquired under the Company's 2019 Employee Stock Purchase Plan since the reporting person's ownership report filed on September 25, 2019.

F6: Shares are held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F7: The option is fully vested and exercisable.